Intervet appoints Ellen de Brabander as a member of the company’s Executive Committee

4 October 2006

Klaus Olbers has enjoyed a 32 year career in our veterinary business in various management positions. He will put his experience into service of Nobilon, Akzo Nobel’s international business on human vaccines in a consulting role. 

Ellen de Brabander joined Intervet in August 2006. After finishing her study in Chemistry at Leiden University and gaining her PhD Ms de Brabander was engaged at Massachusetts Institute of Technology (M.I.T.). She has received a number of awards for her achievements in research a.o. the Golden Medal of the Dutch Royal Chemical Society. In 1991 she started at DSM Research Laboratories, Geleen, The Netherlands. After a successful career in different management positions both in performance materials as well as in pharma she was appointed Vice President Corporate Technology at DSM. 

Ruurd Stolp, President, Intervet, said: “I am pleased that Ellen decided to join Intervet and I am confident, that with the appointment of Ellen, continued successful delivery of innovative products for the animal health market by Intervet’s R&D will be ensured.” 

- end -

Note for the editor
Intervet, a business unit of Akzo Nobel, based in Boxmeer, the Netherlands, with sales of EUR 1,094 million in 2005, is dedicated to research and development, production and marketing of innovative animal health products. Intervet's product range for use in livestock, companion animals, poultry and fish includes vaccines, antiparasitics, anti-infectives, endocrine products and other pharmaceutical specialties. Intervet operates globally with its own marketing organizations. The company currently employs around 5,000 people.

Internet: www.intervet.com

Akzo Nobel is a Global Fortune 500 company and is listed on both the Euronext Amsterdam and NASDAQ stock exchanges. It is also included on the Dow Jones Sustainability Indexes and FTSE4Good Index. Based in the Netherlands, we are a multicultural organization serving customers throughout the world with human and animal healthcare products, coatings, and chemicals. We employ around 61,500 people and conduct our activities in four segments − human and animal health, coatings and chemicals − subdivided into 13 business units, with operating subsidiaries in more than 80 countries. Consolidated revenues for 2005 totaled EUR 13.0 billion. The financial results for the third quarter will be published on October 18, 2006.

Internet: www.akzonobel.com

Not for publication – for more information
Sabine Schueller                         Tel:  +31 (0)485 587085
Communications & Public Affairs   Fax: +31 (0)485 585392
Intervet International bv              communications@intervet.com